Protocol Ledger

NCT04646005 · Phase II · COMPLETED

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Interventional Phase II clinical trial protocol NCT04646005 sponsored by Regeneron Pharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-28 Enrollment: 113 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04646005
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)113 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04646005
Protocol FieldVerified Registry Value
NCT IdentifierNCT04646005
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment113 participants (ACTUAL)
Registered Start Date2021-06-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04646005
Hospital Research SiteLocationSite Profile
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI